Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.45) by 31.11 percent. This is a 55.71 percent increase over losses of $(0.70) per share from the same period last year. The company reported quarterly sales of $23.63 million which beat the analyst consensus estimate of $22.61 million by 4.49 percent. This is a 5.20 percent decrease over sales of $24.92 million the same period last year.
Abbott Reopens Its Michigan Plant Closed Due To Floods: Report
Abbott Laboratories (NYSE:ABT) has reopened its Sturgis, Michigan, baby formula plant, which was shut last month due to heavy…
